세계의 소외열대질환(NTD) 치료제 및 백신 시장 규모 : 제품별, 질환별, 지역 범위별, 예측

Global Neglected Tropical Diseases Drugs And Vaccines Market Size By Product (Drugs, Vaccines), By Disease (Lymphatic Filariasis, Echinococcosis, Leishmaniasis, Dracunculiasis, Dengue, Chikungunya), By Geographic Scope And Forecast

US $ 3,950 ￦ 5,703,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

US $ 4,850 ￦ 7,002,000

PDF & Excel (5 User License)

PDF 및 Excel 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

US $ 7,550 ￦ 10,900,000

PDF & Excel (Enterprise User License)

PDF 및 Excel 보고서를 동일기업내 모든 분들이 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

한글목차

소외열대질환(NTD) 치료제 및 백신 시장 규모와 전망

소외열대질환(NTD) 치료제 및 백신 시장 규모는 최근 몇 년 동안 완만한 성장률로 큰 폭으로 성장하고 있으며, 시장 추정 및 예측 기간(2026-2032년) 동안 크게 성장할 것으로 예측됩니다.

• 소외열대질환(NTD) 치료제 및 백신은 주로 열대 및 아열대 지역 사람들이 주로 발병하고 의료 자원에 대한 접근성이 제한적인 질병을 예방, 치료 및 근절하기 위해 특별히 고안된 의약품 및 예방접종입니다.
• 말라리아, 뎅기열, 리슈만증, 주혈흡충증은 전 세계 수백만 명이 앓고 있는 질병 중 하나이며, 대부분 저소득 국가에 살고 있습니다.
• NTD 치료제는 많은 병원체에 의한 감염병을 치료하기 위한 것이고, 백신은 면역체계를 활성화시켜 이들 질환의 발병을 예방하기 위한 것입니다.
• 또한, 이러한 치료법은 일반적으로 잘 알려진 감염성 질환에 비해 관심이나 자금이 부족한 질병을 대상으로 함으로써 세계보건기구(WHO)의 세계보건계획에서 중요한 역할을 하고 있으며, 이를 통해 전 세계적인 건강 격차 해소와 의료 접근의 형평성을 촉진하고 있습니다.

열대병 치료제 및 백신 세계 시장 역학

열대병 치료제 및 백신 시장을 형성하고 있는 주요 시장 역학은 다음과 같습니다.

주요 시장 성장 촉진요인

• 세계 보건 이니셔티브 및 자금 조달 증가: WHO, 게이츠 재단 및 기타 비정부기구가 주도하는 세계 보건 이니셔티브는 NTD의 연구개발에 대한 자금 제공 및 지원을 확대하고 있습니다. 이러한 지원은 필요한 치료제와 백신을 공급하여 특정 질병을 퇴치하거나 억제하기 위한 것으로, 시장을 주도하고 있습니다.
• 연구 개발의 기술 발전: 생명공학 및 유전학의 발전으로 NTD에 대한 치료법과 백신의 발견이 가속화되고 있습니다. 첨단 기술의 활용은 새로운 치료법과 백신의 발견을 가속화하고 시장 성장을 가속하고 있습니다.
• NTDs에 대한 인식 제고 및 정부 지원: NTDs에 대한 전 세계적인 인식이 높아지면서 NTDs 퇴치를 위한 정부 및 국제적인 지원이 증가하고 있으며, NTDs의 예방, 관리 및 퇴치를 목표로 하는 국가 보건 프로그램 및 정책은 실행 가능한 치료 솔루션의 필요성을 촉진하고 있습니다.
• 협력과 파트너십: 정부, 제약사, 비영리단체 간의 전략적 제휴는 NTD 치료제와 백신의 개발 및 제공에 필수적입니다. 이러한 제휴는 연구, 자금 조달, 치료의 접근성을 높여 시장 성장에 큰 기여를 할 수 있습니다.

주요 과제

• 제약회사에 대한 경제적 인센티브의 한계: Neglected Tropical Diseases는 주로 저개발국가의 저소득층을 대상으로 하기 때문에 제약회사가 연구개발에 투자할 상업적 인센티브가 거의 없습니다. 이러한 재정적 동기부여의 부족은 혁신적이고 효과적인 의약품의 개발을 방해하고 있습니다.
• 복잡한 의약품 개발 프로세스: NTD 치료제와 백신을 개발하는 과정은 복잡하고 비용과 시간이 많이 소요됩니다. 대규모 임상 연구의 필요성, 규제 당국의 승인, 이들 질병의 영향을 가장 많이 받는 지역에서의 조사의 어려움 등이 시장 성장에 영향을 미칠 수 있습니다.
• 유통 및 접근성 문제: 외딴 지역과 빈곤 지역에서 효과적인 의약품과 백신의 유통은 큰 문제입니다. 열악한 인프라, 의료 시설의 부족, 정치적 불안으로 인해 치료가 필요한 사람들이 치료를 받을 수 없고, 사용 가능한 솔루션의 효과를 제한합니다.

주요 동향 :

• 민관협력(PPP) 활용 확대: 정부, 민간기업, 비영리단체 간의 협력이 증가하고 있습니다. 이러한 협력 관계는 각 부문의 강점을 활용하여 NTD 치료제 및 백신의 자금 조달, 연구, 유통을 촉진하고, 시장 성장과 지원 활동을 개선하기 위해 각 부문의 강점을 활용하고 있습니다.
• 백신 개발에 집중: 백신의 예방적 특성과 비용 효율성을 고려하여 NTD 백신에 대한 연구가 강조되고 있으며, mRNA 백신, 유전자 재조합 백신 등 백신 기술의 혁신은 이러한 질병을 예방하기 위해 연구되고 있으며, 이 분야의 주요 동향을 보여주고 있습니다. 큰 흐름을 보이고 있습니다.
• 세계보건기구(WHO)는 NTD 치료 및 백신 접종에 대한 접근성 향상에 점점 더 많은 노력을 기울이고 있으며, 비용 절감 협상, 공급망 강화, 감염된 지역의 의료 시설 개선 등 NTD의 세계적 부담을 최소화하기 위한 노력을 기울이고 있습니다. 시장 역학을 형성할 수 있도록 노력하고 있습니다.

목차

제1장 세계의 소외열대질환(NTD) 치료제 및 백신 시장 서론

• 시장 개요
• 조사 범위
• 전제조건

제2장 주요 요약

제3장 VERIFIED MARKET RESEARCH의 조사 방법

• 데이터 마이닝
• 밸리데이션
• 1차 자료
• 데이터 소스 리스트

제4장 세계의 소외열대질환(NTD) 치료제 및 백신 시장 전망

• 개요
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
• Porter's Five Forces 모델
• 밸류체인 분석

제5장 세계의 소외열대질환(NTD) 치료제 및 백신 시장 : 제품별

• 개요
• 의약품
• 백신

제6장 세계의 소외열대질환(NTD) 치료제 및 백신 시장 : 질환별

• 개요
• 림프사상충증
• 에키노코쿠아증
• 리슈마니아증
• 드라쿤쿨라리아증
• 뎅기열
• 치쿤구니야열
• 기타

제7장 세계의 소외열대질환(NTD) 치료제 및 백신 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 기타 유럽
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 기타 아시아태평양
• 세계 기타 지역
  • 라틴아메리카
  • 중동 및 아프리카

제8장 세계의 소외열대질환(NTD) 치료제 및 백신 시장 경쟁 구도

• 개요
• 기업의 시장 순위
• 주요 개발 전략

제9장 기업 개요

• Johnson & Johnson
• GlaxoSmithKline
• Sanofi
• Novartis
• Bayer
• Eli Lilly and Company
• Pfizer
• AbbVie Inc.
• Amgen Inc.
• Gilead Sciences Inc.

제10장 주요 발전

• 제품 출시 및 개발
• 인수합병(M&A)
• 사업 확대
• 파트너십과 제휴

제11장 부록

• 관련 조사

LSH

영문 목차

영문목차

Neglected Tropical Diseases Drugs And Vaccines Market Size And Forecast

The Neglected Tropical Diseases Drugs And Vaccines Market size is growing at a moderate pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e.2026 to 2032.

• Neglected Tropical Diseases (NTD) Drugs and vaccines are pharmaceuticals and vaccinations specifically designed to prevent, treat, or eradicate diseases that primarily affect populations in tropical and subtropical regions with limited access to healthcare resources.
• Malaria, dengue fever, leishmaniasis, and schistosomiasis are among the diseases that affect millions of people globally, with the majority of them living in low-income nations.
• NTD medicines are intended to treat infections caused by numerous pathogens, whilst vaccines attempt to activate the immune system and prevent the onset of these diseases.
• Furthermore, these interventions play an important role in global health initiatives by targeting diseases that generally receive less attention and financing than more prominent infectious diseases, thereby reducing health inequities and promoting fairness in healthcare access on a worldwide scale.

Global Neglected Tropical Diseases Drugs And Vaccines Market Dynamics

The key market dynamics that are shaping the Neglected Tropical Diseases Drugs And Vaccines Market include:

Key Market Drivers

• Increased Global Health Initiatives and Funding: Global health initiatives led by WHO, the Gates Foundation, and other non-governmental organizations have expanded financing and support for NTD research and development. This support seeks to eliminate or control certain diseases by supplying required treatments and vaccines, hence driving the market.
• Technological Advancements in Research and Development: Advances in biotechnology and genetics have accelerated the discovery of treatments and vaccines for NTDs. The use of advanced techniques accelerates the discovery of novel treatment approaches and vaccines, driving market growth.
• Rising Awareness and Government Support: There is an increasing global awareness of NTDs, which has led to increased government and international assistance for combating these diseases. National health programs and policies aimed at NTD prevention, control, and elimination promote the need for viable treatment solutions.
• Collaborations and Partnerships: Strategic alliances among governments, pharmaceutical corporations, and non-profit groups are critical for the development and delivery of NTD treatments and vaccines. These alliances make research, funding, and therapy more accessible, hence contributing considerably to market growth.

Key Challenges:

• Limited Financial Incentives for Pharmaceutical Companies: Neglected Tropical Diseases primarily affect low-income populations in underdeveloped nations, providing few commercial incentives for pharmaceutical corporations to invest in R&D. This lack of financial motive hampers the development of innovative and effective medicines.
• Complex Drug Development Process: The drug and vaccine development process for NTDs is complicated, expensive, and time-consuming. Challenges include the requirement for extensive clinical studies, regulatory approvals, and the difficulty of doing research in the regions most impacted by these diseases, all of which impact market growth.
• Distribution and Access Challenges: Effective medicine and vaccine distribution in remote and poor locations is a major concern. Poor infrastructure, a lack of healthcare facilities, and political instability make treatments inaccessible to individuals in need, limiting the effectiveness of available solutions.

Key Trends:

• Increased Use of Public-Private Partnerships (PPPs): Collaborations between governments, commercial sector entities, and non-profit groups are increasing. These collaborations use the strengths of each sector to increase funding, research, and distribution efforts for NTD medications and vaccines, hence improving market growth and outreach.
• Focus on Vaccine Development: Given vaccines' preventive nature and cost-effectiveness, there is a growing emphasis on NTD vaccine research. Innovations in vaccine technology, such as mRNA and recombinant vaccines, are being investigated to prevent these diseases, indicating a significant trend in the field.
• Expanding Access Through Global Health Initiatives: Global health programs are increasingly focusing on improving access to NTD treatments and vaccinations. Efforts to negotiate lower costs, strengthen supply chains, and improve healthcare facilities in impacted areas aim to minimize the worldwide burden of NTDs, which will shape market dynamics.

Global Neglected Tropical Diseases Drugs And Vaccines Market Regional Analysis

Here is a more detailed regional analysis of the Neglected Tropical Diseases Drugs And Vaccines Market:

Asia Pacific:

• According to VMR Analyst, Asia Pacific is estimated to dominate the Neglected Tropical Diseases Drugs And Vaccines Market during the forecast period. A large proportion of the global population is affected by Neglected Tropical Diseases (NTDs) in Asia Pacific. The high prevalence of these diseases in the region generates a need for effective treatments and vaccines, establishing Asia Pacific as a critical market for NTD therapies.
• Governments and private sectors in the Asia-Pacific region are investing more in healthcare infrastructure and services. This includes major investment in NTD prevention, treatment, and eradication, which will help to boost the region's medication and vaccine markets.
• The region has emerged as a hotspot for collaborative R&D initiatives aimed at NTDs, with partnerships comprising local governments, international health organizations, and pharmaceutical corporations. These agreements improve the development and availability of new therapies and vaccinations.
• Furthermore, in Asia Pacific countries, improvements in healthcare access and delivery systems have made it easier to distribute and administer NTD treatments and vaccines. Enhanced healthcare infrastructure and higher healthcare spending help to explain the region's dominance in the NTD medicines and vaccines market.

Latin America:

• In Latin America, governments and non-governmental organizations (NGOs) have launched comprehensive efforts to control and eliminate NTDs. These initiatives include mass drug administration campaigns and vaccination drives, which have considerably increased the demand for NTD-related pharmaceuticals and vaccines in the region.
• Latin America benefits from international financing and cooperation to tackle NTDs. Global health organizations such as PAHO, WHO, and the Gates Foundation provide critical financial and technical support for medicine and vaccine research, development, and distribution, hence boosting market growth.
• Latin America has experienced a surge in regional collaboration on NTD research and development. Consortia of local research institutions, universities, and pharmaceutical businesses are developing creative methods to combat NTDs, promoting local market growth.
• Furthermore, the region's healthcare infrastructure and services are improving significantly, making it easier to deliver NTD treatments and vaccines. Improved healthcare systems, as well as increased healthcare access in rural and underprivileged areas, are significant drivers of Latin America's growing market for NTD interventions.

Middle East & Africa:

• Due to socioeconomic and climatic variables, the Middle East and Africa (MEA) region has a high incidence of neglected tropical diseases. The high prevalence of NTDs creates an urgent need for effective medications and vaccines, accelerating market growth in this region.
• MEA governments, with the backing of international health organizations, are increasingly focused on NTD control and elimination programs. These activities frequently include mass drug administration and immunization campaigns, which directly increase demand for NTD-related drugs.
• Healthcare investments in the MEA region have increased significantly, with an emphasis on enhancing infrastructure and access. This includes investments in hospitals, clinics, and distribution networks for medications and vaccinations, which will expand the reach and impact of NTD interventions.
• Furthermore, MEA countries and worldwide partners are collaborating to promote NTD research and development. These collaborations seek to develop and implement effective treatments and vaccinations adapted to the region's specific needs, hence promoting the growth of the NTD medications and vaccines market.

Global Neglected Tropical Diseases Drugs And Vaccines Market: Segmentation Analysis

The Global Neglected Tropical Diseases Drugs And Vaccines Market is segmented based on Product, Disease, And Geography.

Neglected Tropical Diseases Drugs And Vaccines Market, By Product

• Drugs
• Vaccines

Based on Product, the market is segmented into Drugs and Vaccines. The drugs segment is estimated to dominate the Neglected Tropical Diseases Drugs And Vaccines Market due to the acute requirement for therapy in affected people, medications are the primary intervention approach. Drugs are utilized not only for treatment but also for preventative chemotherapy in high-risk populations, which can be implemented faster than vaccine development and distribution. Furthermore, the wider choice of accessible pharmacological therapies for numerous NTDs, as opposed to vaccinations, which are only available for a few diseases, contributes to pharmaceuticals' bigger market share.

Neglected Tropical Diseases Drugs And Vaccines Market, By Disease

• Lymphatic Filariasis
• Echinococcosis
• Leishmaniasis
• Dracunculiasis
• Dengue
• Chikungunya
• Others

Based on Disease, the market is segmented into Lymphatic Filariasis, Echinococcosis, Leishmaniasis, Dracunculiasis, Dengue, Chikungunya, and Others. The Dengue disease segment is estimated to hold the majority share in the forecast period in the Neglected Tropical Diseases Drugs And Vaccines Market owing to dengue fever's extensive prevalence in tropical and subtropical locations around the world, which affects millions of people each year. The disease's high occurrence rate, combined with the serious health issues it can bring, necessitates extensive research and development efforts for effective dengue vaccines and therapeutic medications. Furthermore, increasing public health initiatives and financing targeted at preventing dengue transmission, such as large-scale vaccination campaigns and community awareness programs, add to the need for dengue-related pharmaceutical products.

Key Players

• The "Neglected Tropical Diseases Drugs And Vaccines Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Johnson & Johnson, GlaxoSmithKline, Sanofi, Merck & Co., Novartis, Bayer, Eli Lilly and Company, Pfizer, AbbVie Inc., Amgen Inc., Gilead Sciences Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., and Roche Diagnostics International Ltd.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Global Neglected Tropical Diseases Drugs And Vaccines Market Recent Developments
• In March 2024, the World Health Organization (WHO) emphasized African health ministers' commitment to eliminating malaria deaths. This represents a larger effort to control diseases that frequently overlap with neglected tropical diseases, even if it is not a direct NTD medicine or vaccine.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Drugs
• 5.3 Vaccines

6 GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET, BY DISEASE

• 6.1 Overview
• 6.2 Lymphatic Filariasis
• 6.3 Echinococcosis
• 6.4 Leishmaniasis
• 6.5 Dracunculiasis
• 6.6 Dengue
• 6.7 Chikungunya
• 6.8 Others

7 GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Johnson & Johnson
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 GlaxoSmithKline
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Sanofi
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Novartis
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Bayer
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Eli Lilly and Company
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Pfizer
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 AbbVie Inc.
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Amgen Inc.
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 Gilead Sciences Inc.
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 KEY DEVELOPMENTS

• 10.1 Product Launches/Developments
• 10.2 Mergers and Acquisitions
• 10.3 Business Expansions
• 10.4 Partnerships and Collaborations

11 Appendix

• 11.1 Related Research

관련자료